NovoCure (NVCR) Equity Ratio (2014 - 2026)

NovoCure has disclosed Equity Ratio across 13 years of filings, most recently posting 0.42 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.42, up 44.81% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.42 (up 44.81% YoY), and the FY2025 annual result was 0.42, up 45.82% from the prior year.
• Equity Ratio came in at 0.42 for Q1 2026 at NovoCure, down from 0.42 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.42 in Q4 2025 to a low of 0.25 in Q3 2025.
• The 5-year median for Equity Ratio is 0.34 (2023), against an average of 0.34.
• Across the five-year window, Equity Ratio retreated 16.79% in 2024 and soared 45.82% in 2025, its largest moves.
• NovoCure's Equity Ratio stood at 0.37 in 2022, then declined by 14.57% to 0.32 in 2023, then dropped by 8.22% to 0.29 in 2024, then jumped by 45.82% to 0.42 in 2025, then retreated by 0.84% to 0.42 in 2026.
• The last three Equity Ratio figures came in at 0.42 (Q1 2026), 0.42 (Q4 2025), and 0.25 (Q3 2025), per Business Quant data.